JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Ziltivekimab is a humanized monoclonal antibody directed against the IL-6 ligand. It was developed to inhibit pro-inflammatory IL-6 signaling in conditions that are associated with systemic inflammation, including atherosclerosis, chronic kidney disease, and rheumatoid arthritis, and it has also been explored for anti-tumor activity. The Fc domain of ziltivekimab has been engineered to extend its half-life by increasing affinity for FcRn.